MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412502 | Name: Cefcanel free acid

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefcanel is a semisynthetic third-generation cephalosporin with antibacterial activity. Cefcanel is active against the species E. coli, K. aerogenes and Proteus mirabilis; H. influenzae and M. catarrhalis has reasonable susceptibility. Cefcanel inhibits 90% of S. aureus strains at 2 µg/ml, irrespective of the presence of a β-lactamase. Cefcanel binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.

Chemical Structure

Cefcanel free acid
Cefcanel free acid
CAS#41952-52-7 (free acid)

Theoretical Analysis

MedKoo Cat#: 412502

Name: Cefcanel free acid

CAS#: 41952-52-7 (free acid)

Chemical Formula: C19H18N4O5S3

Exact Mass: 478.0439

Molecular Weight: 478.56

Elemental Analysis: C, 47.69; H, 3.79; N, 11.71; O, 16.72; S, 20.10

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
41952-52-7 (free acid) 30034-02-7 (sodium)
Synonym
Cefcanel, ALL103; ALL-103; ALL 103; KY 087; KY-087; KY087; Cefcanel free acid;
IUPAC/Chemical Name
(6R,7R)-7-((R)-2-hydroxy-2-phenylacetamido)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
InChi Key
VDFFPBOAOLQAJV-SUYBPPKGSA-N
InChi Code
InChI=1S/C19H18N4O5S3/c1-9-21-22-19(31-9)30-8-11-7-29-17-12(16(26)23(17)13(11)18(27)28)20-15(25)14(24)10-5-3-2-4-6-10/h2-6,12,14,17,24H,7-8H2,1H3,(H,20,25)(H,27,28)/t12-,14-,17-/m1/s1
SMILES Code
O=C(C(N12)=C(CSC3=NN=C(C)S3)CS[C@]2([H])[C@H](NC([C@H](O)C4=CC=CC=C4)=O)C1=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 478.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Grunfeld A, Sinclair P, Nicolle L; Canadian Tonsillitis Study Group. Cefcanel daloxate versus penicillin in acute streptococcal pharyngotonsillitis. Can J Infect Dis. 1994 May;5(3):119-24. doi: 10.1155/1994/531572. PMID: 22346486; PMCID: PMC3250823. 2: Edwall B, Slettevold L, Thurmann-Nielsen E, Walstad R, Torrång A, Dahl K. Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function. J Antimicrob Chemother. 1994 Feb;33(2):281-8. doi: 10.1093/jac/33.2.281. PMID: 8182009. 3: Holst E, Rollof J, Miörner H. In vitro activities of cefcanel and some other cephalosporins against Pasteurella multocida. Antimicrob Agents Chemother. 1989 Dec;33(12):2142-3. doi: 10.1128/aac.33.12.2142. PMID: 2619280; PMCID: PMC172837. 4: Chin NX, Gu JW, Neu HC. In vitro activity of cefcanel versus other oral cephalosporins. Eur J Clin Microbiol Infect Dis. 1991 Aug;10(8):676-82. doi: 10.1007/BF01975825. PMID: 1748125. 5: Edwall B, Arvidsson A, Lake-Bakaar D, Lanbeck-Vallén K, Yisak W. Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. Drug Metab Dispos. 1993 Jan-Feb;21(1):171-7. PMID: 8095213. 6: Nicolle LE, Hoepelman AI, Floor M, Verhoef J, Norgard K. Comparison of three days' therapy with cefcanel or amoxicillin for the treatment of acute uncomplicated urinary tract infection. Scand J Infect Dis. 1993;25(5):631-7. doi: 10.3109/00365549309008553. PMID: 8284649. 7: Lanbeck-Vallén K, Carlqvist J. Determination of cefcanel in plasma and urine by high-performance liquid chromatography using coupled columns, after administration of the new cephalosporin prodrug cefcanel daloxate hydrochloride. J Chromatogr. 1992 Jul 1;578(1):71-6. doi: 10.1016/0378-4347(92)80226-g. PMID: 1400788. 8: Nord CE, Lindmark A, Persson I. Comparative antibacterial activity of the new cephalosporin cefcanel against anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 1989 Jun;8(6):550-1. doi: 10.1007/BF01967478. PMID: 2548866. 9: Löwdin E, Tornqvist IO, Cars O. The postantibiotic effect of cefcanel on beta-hemolytic streptococci group A in vitro and in vivo. Scand J Infect Dis Suppl. 1990;74:190-4. PMID: 2097708. 10: Magni L, Lionell C. In vivo efficacy of cefcanel daloxate in comparison with cefaclor. Scand J Infect Dis Suppl. 1990;74:185-9. PMID: 2097707.